Iowa SF552 mandates a review of anti-obesity medications by the Department of Health and Human Services and the Department of Administrative Services.

Iowa SF552 requires the Department of Health and Human Services and the Department of Administrative Services to review anti-obesity medications, including GLP-1 agonists, for effectiveness in weight loss, impact on comorbidities, and potential cost savings. The review will also consider eligibility requirements and short-term and long-term costs associated with coverage. The departments must submit a report to the general assembly by January 5, 2026, detailing their findings, proposed eligibility requirements, and any associated costs.

Iowa SF552 mandates a review of anti-obesity medications by the Department of Health and Human Services and the Department of Administrative Services.

Iowa SF552 requires the Department of Health and Human Services and the Department of Administrative Services to review anti-obesity medications, including GLP-1 agonists, for effectiveness in weight loss, impact on comorbidities, and potential cost savings. The review will also consider eligibility requirements and short-term and long-term costs associated with coverage. The departments must submit a report to the general assembly by January 5, 2026, detailing their findings, proposed eligibility requirements, and any associated costs.